Drägerwerk AG & Co. KGaA
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DGWPF research report →
Price Chart
About the company
Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is an international enterprise specializing in medical and safety technology, with operations spanning Europe, the Americas, Africa, Asia, and Australia. For the healthcare sector, the company engineers, produces, and commercializes comprehensive solutions, apparatus, and related services tailored for acute care environments, such as emergency, perioperative, critical, and perinatal settings.
- CEO
- Stefan A. Drager
- IPO
- 2012
- Employees
- 16,687
- HQ
- Lübeck, SH, DE
Get TickerSpark's AI analysis on DGWPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.56B
- P/E
- 12.94
- Fwd P/E
- 9.91
- PEG
- 0.32
- P/S
- 0.54
- P/B
- 1.28
- EV/EBITDA
- 4.70
- Div Yield
- 1.94%
- Gross Margin
- 46.39%
- Op Margin
- 7.40%
- Net Margin
- 4.72%
- ROE
- 10.20%
- ROIC
- 7.59%
Latest fiscal year · YoY change
- Revenue
- $3.48B+3.3%
- Gross Profit
- $1.51B+0.2%
- Op Income
- $238.19M
- Net Income
- $139.44M+12.1%
- EPS
- $7.44+12.6%
- OCF Growth
- +42.4%
- FCF Growth
- +60.8%
- 52W High
- $102.31
- 52W Low
- $67.14
- 50D MA
- $92.89
- 200D MA
- $84.61
- Beta
- 0.62
- RSI (14)
- 10
- Avg Volume
- 9
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Drägerwerk posted stronger 9M 2026 sales, earnings and cash flow, kept full-year guidance unchanged, and pointed to defense and the lifted FDA warning letter as longer-term supports.· October 29, 2026
- 9M order intake rose to around EUR 2.7 billion, net sales increased to around EUR 2.5 billion, and EBIT reached around EUR 112 million with a 4.6% margin.
- Gross margin improved to 46.8% in the first 9 months, helped by customs refunds; management said the net tariff effect was still about minus EUR 2 million year to date.
- Free cash flow jumped to around EUR 114 million from around EUR 16 million last year, while net financial debt fell to around EUR 106 million.
- Full-year 2026 guidance was confirmed: 2% to 6% net sales growth and a 6% to 8% EBIT margin.
- Management highlighted defense order momentum, a lifted FDA warning letter, and a potential future boost from the Ambition 2030 roadmap to be discussed on November 18.
Reported 9M 2026 figures included order intake of around EUR 2.7 billion, net sales of around EUR 2.5 billion, EBIT of around EUR 112 million, and an EBIT margin of 4.6%. Net sales grew by around EUR 110 million, EBIT rose by roughly EUR 35 million, and free cash flow increased to around EUR 114 million from around EUR 16 million a year earlier. Gross margin was 46.8%, up 1.7 percentage points, and net financial debt fell by around EUR 116 million to around EUR 106 million; the net effect from tariffs year to date was about minus EUR 2 million. For full year 2026, management reaffirmed guidance for net sales growth of 2% to 6% and an EBIT margin of 6% to 8%.
Stefan Dräger described 2026 as “very successful” so far and said the company continues to see good demand across the business, with the fourth quarter expected to be the best quarter of the year. He said there were no unusual product or regional issues driving the outlook, though China remains below expectations. He also emphasized strategic tailwinds from defense opportunities, the end of the FDA warning letter after almost seven years, and the upcoming Capital Markets Day / Ambition 2030 update.
Gert-Hartwig Lescow emphasized that growth rates were currency-adjusted and said order intake rose 3.6% in 9M, while net sales rose 5.3%. He cited gross margin improvement to 46.8% from customs refunds, but also noted functional expenses increased 6.1% in 9M due to personnel, logistics, IT, and one-time costs, including higher collective-bargaining-related expenses and project costs at the new Lübeck distribution center. He highlighted operating cash flow of around EUR 175 million, free cash flow up around EUR 98 million, net financial debt down to around EUR 106 million, and an equity ratio of about 52%. He also said the dividend policy remains unchanged, with at least 30% of net income paid out as dividend.
Analysts pressed on Medical margins, asking how the company can move toward its 10% margin ambition, and management pointed to net sales growth, portfolio mix, better monitoring positioning after the warning letter, and higher research efficiency, while also noting tariffs still help year to date. On functional costs, management acknowledged Q4 requires tighter spending control and said some one-off effects will fade, but they did not provide a more precise bridge. On Germany defense orders, management said a major customer order is worth low double-digit millions and will be delivered over 2 to 3 years, while the broader defense ambition remains around EUR 300 million versus roughly EUR 100 million in 2025. On China, management said demand is below expectations, Chinese competitors are also seeing domestic declines, and potential 2027 headwinds could include supply chain shortages tied to the AI boom, while defense and the FDNY tender were cited as possible tailwinds.
The bull case from this call is that underlying demand remains solid, with stronger orders in Safety and a better third quarter trend in the group overall. Cash generation improved sharply, debt came down, and management sees additional upside from defense contracts, the lifted FDA warning letter, and possible wins in high-profile tenders like FDNY. If execution continues, the company still has room to expand margins and potentially support the Ambition 2030 framework.
The main risks discussed were weaker-than-expected Medical order momentum, especially in China, and the fact that tariff-related benefits and some one-off items boosted margins and earnings year to date. Management also signaled that Q4 functional cost control must be tight, implying limited room for error. In addition, China remains soft, Americas Medical growth was pressured by prior-year comparisons, and potential 2027 headwinds could include supply chain shortages and currency effects.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 23.4%
- Shares Outstanding
- 18.76M
- Float Shares
- 4.40M
Our DGWPF coverage
Recent articles, reports, and earnings notes.
No research on DGWPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DGWPF report →Drägerwerk AG & Co. KGaA (DGWPF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Contrasting Drägerwerk AG & Co. KGaA (OTCMKTS:DGWPF) and Butterfly Network (NYSE:BFLY)
defenseworld.net · Aug 10
Drägerwerk AG & Co. KGaA (DGWPF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 30
Drägerwerk AG & Co. KGaA (DGWPF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 24
Drägerwerk AG & Co. KGaA (DGWPF) Q3 2025 Earnings Call Transcript
seekingalpha.com · Oct 29
Drägerwerk AG & Co. KGaA (DGWPF) Q2 2025 Earnings Call Transcript
seekingalpha.com · Jul 29
Drägerwerk AG & Co KGaA (DGWPF) Q1 2025 Earnings Call Transcript
seekingalpha.com · May 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.